Пређи на садржај

Indantadol

С Википедије, слободне енциклопедије
Indantadol
IUPACime
N-(2,3-dihidro-1H-inden-2-il)glicinamid
Klinički podaci
Način primeneOralno
Pravni status
Pravni status
  • Nije kontrolisana supstanca
Identifikatori
CAS broj202844-10-8
ATC kodnone
ChemSpider16017060
UNIIZ3867B9SQPДаY
Hemijski podaci
FormulaC11H14N2O
Molarna masa190,24 g/mol
  • NCC(=O)NC1Cc2ccccc2C1

Indantadol(CHF-3381,V-3381) jelekkoje je izučavan za moguću primenu kaoantikonvulsantineuroprotectiv,i koji se razvija kao potencijalni tretmanneuropatičkog bolaihroničnog kašljauEvropi.[1][2][3][4][5][6][7][8]On takođe deluje kaokompetitivni,reverzibilni,ineselektivniinhibitor monoaminske oksidaze,[5][6][9]i kaonekompetitivniantagonist NMDA receptoraniskogafiniteta.[1][2][10]

  1. ^абVilletti G; Bregola G; Bassani F; et al. (2001).„Preclinical evaluation of CHF3381 as a novel antiepileptic agent”.Neuropharmacology.40(7): 866—78.PMID11378157.doi:10.1016/S0028-3908(01)00026-0.
  2. ^абGandolfi O; Bonfante V; Voltattorni M; et al. (2001).„Anticonvulsant preclinical profile of CHF 3381: dopaminergic and glutamatergic mechanisms”.Pharmacology, Biochemistry, and Behavior.70(1): 157—66.PMID11566153.doi:10.1016/S0091-3057(01)00591-3.
  3. ^Zucchini S, Buzzi A, Bergamaschi M, Pietra C, Villetti G, Simonato M (2002).„Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist”.Neuroreport.13(16): 2071—4.PMID12438928.doi:10.1097/00001756-200211150-00016.
  4. ^Villetti G; Bergamaschi M; Bassani F; et al. (2003).„Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain”.The Journal of Pharmacology and Experimental Therapeutics.306(2): 804—14.PMID12750440.doi:10.1124/jpet.103.050039.
  5. ^аб„CHF 3381”.Drugs in R&D.5(1): 28—30. 2004.PMID14725488.
  6. ^абMattia C, Coluzzi F (2007). „Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain”.IDrugs: the Investigational Drugs Journal.10(9): 636—44.PMID17786847.
  7. ^„IN-STEP Phase IIb study results”.Архивирано изоригинала13. 08. 2014. г.
  8. ^„Vernalis initiates Pilot Study of V3381 in patients with chronic cough”.Архивирано изоригинала13. 08. 2014. г.
  9. ^Mathiesen O, Imbimbo BP, Hilsted KL, Fabbri L, Dahl JB (2006).„CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model”.The Journal of Pain.7(8): 565—74.PMID16885013.doi:10.1016/j.jpain.2006.02.004.
  10. ^Barbieri M; Bregola G; Buzzi A; et al. (2003).„Mechanisms of action of CHF3381 in the forebrain”.British Journal of Pharmacology.139(7): 1333—41.PMC1573965Слободан приступ.PMID12890713.doi:10.1038/sj.bjp.0705381.